Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01696058
- Testing
- Tiotropium, Olodaterol
- Where
- 94 sites in United States
- Volunteers
- 1,137 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting
This is a cross-sectional study to determine the prevalence of symptomatic airway obstruction using the LFQ as a screening tool in primary care patients with a history of cigarette smoking and to provide descriptive data of this…
- Trial name
- NCT01013948
- Testing
- Non-Interventional
- Where
- 40 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD, COPD Bronchitis
NBMI - Clinical Study on COPD
A pilot study to explore safety of the treatment with the antioxidant and metal chelator NBMI in COPD patients. Investigational product: NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide), INN: Emeramide Indication: Mild, moderate…
- Trial name
- Emera003COPD (NCT03123692)
- Testing
- Emeramide
- Volunteers
- 12 people
- Sponsor
- EmeraMed
Chronic Obstructive Pulmonary Disease, Emphysema
Endobronchial Valve for Emphysema Palliation Trial (VENT)
The purpose of this study is to assess the safety and efficacy of the Emphasys Endobronchial Valve (EBV) and procedure (with pulmonary rehabilitation) compared to optimal medical management (with pulmonary rehabilitation) in…
- Trial name
- NCT00129584
- Testing
- Emphasys Endobronchial Valve and procedure
- Volunteers
- 270 people
- Sponsor
- Emphasys Medical
COPD
Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Determine the affect of the Portable Oxygen Concentrator (POC) on improvements in: 1.
- Trial name
- NCT01948544
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- StratiHealth
COPD
Comparing Pressure Based and Dilution Based Total Lung Capacity Measurements in COPD Patients for Lung Function Diagnostics
Total Lung Capacity (TLC) of the lungs can be determined using a pressure based method (i.e. by body plethysmography) or it can be determined using a dilution based method (i.e.
- Trial name
- NCT04531293
- Testing
- Respiratory Analysis System
- Where
- Switzerland
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ndd Medizintechnik AG
COPD
Study in Patients With COPD
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective compared to the control drug.
- Trial name
- NCT00215384
- Testing
- Formoterol Fumarate
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dey
Chronic Obstructive Pulmonary Disease (COPD)
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study is investigating how patients with severe stable state COPD perceive the variability of their symptoms throughout the day, the week and the year; the impact of these variations on their daily activities or sleep…
- Trial name
- NCT00722267
- Where
- 606 sites in Austria, Belgium and 15 more
- Volunteers
- 7,400 people
- Sponsor
- AstraZeneca
Asthma, COPD
An Open Study to Assess the Robustness of the CRC749 Inhaler
To confirm the robustness of the CRC749 inhaler.
- Trial name
- NCT02474017
- Testing
- MGR001, CRC749 inhaler
- Where
- 2 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Mylan Pharma UK Ltd.
Chronic Obstructive Pulmonary Disease
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers
This study will look at the safety and tolerability of TPI 1100 in healthy volunteers and look at pharmacodynamic (PD) effect on mRNA expression of PDE 4B/D \& 7A in blood and in sputum.
- Trial name
- NCT00914433
- Testing
- TPI 1100
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syntara
Chronic Diseases
Evaluation of the Performance of an e-Health System
Prospective, non-randomized, open-label, pilot study conducted in a single group of 30 evaluable patients, i.e. patients completing an approximate 3 month follow-up.
- Trial name
- NCT02803489
- Testing
- medical device intervention
- Where
- 6 sites in France
- Volunteers
- 23 people
- Sponsor
- Air Liquide Santé International
Chronic Obstructive Pulmonary Disease
A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the effects of AZD1236 compared with placebo ("inactive substance") in COPD patients by analysing biomarkers for inflammation and tissue degradation in blood, urine and sputum.
- Trial name
- BICO (NCT00758706)
- Testing
- AZD1236
- Where
- 10 sites in Denmark, Finland and 2 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
COPD
To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to assess and compare the pharmacokinetics (PK) of Tiotropium delivered via Breath Actuated Inhaler (BAI) (4.5 mcg/day or 9.0 mcg/day), SPIRIVA®, HandiHaler®, (18 mcg/day) and Respimat® Soft…
- Trial name
- NCT01785433
- Testing
- Tiotropium HFA BAI 4.5 mcg, Tiotropium HFA BAI 9.0 mcg, SPIRIVA® HandiHaler® 18 mcg/day
- Where
- 5 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disorder
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg)…
- Trial name
- telos (NCT02766608)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg
- Where
- 259 sites in United States, Canada and 6 more
- Volunteers
- 2,389 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)
A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.
- Trial name
- NCT00482235
- Testing
- MK0359
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis
The main objective of the current trial is to investigate safety, tolerability and pharmacokinetics of BI 113608 in COPD patients with symptoms of chronic bronchitis.
- Trial name
- NCT01958008
- Testing
- BI 113608 high dose b.i.d., BI 113608 low dose b.i.d.
- Where
- 6 sites in Germany
- Volunteers
- 84 people
- Sponsor
- Boehringer Ingelheim
COPD
Validation of a Digital Platform for Functional Respiratory Rehabilitation
Chronic Obstructive Pulmonary Disease (COPD), characterized by persistent airflow limitation in the respiratory airways, is a chronic condition that affects millions of people worldwide.
- Trial name
- ReHub (NCT06252818)
- Testing
- ReHub
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Bio-Sensing Solutions S.L. (DyCare)
COPD, Chronic Obstructive Pulmonary Disease
Study of Ambulatory Respiratory Assist Device in Chronic Obstructive Pulmonary Disease Patients
The study is a two-part small scale, open-label, pilot study to evaluate feasibility and proof-of-concept for a respiratory assist medical device.
- Trial name
- NCT03531489
- Testing
- AIR-AD
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Right-Air
Chronic Obstructive Pulmonary Disease
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT00970268
- Testing
- Aclidinium bromide
- Where
- 83 sites in United States, Canada
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of…
- Trial name
- NCT00206154
- Testing
- Budesonide/formoterol pMDI, Budesonide pMDI, Formoterol Turbuhaler
- Where
- 212 sites in United States, Czechia and 3 more
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.